Recent advances in the development of Aurora kinases inhibitors in hematological malignancies

被引:9
|
作者
Choudary, Iqra [1 ]
Barr, Paul M. [1 ]
Friedberg, Jonathan [1 ]
机构
[1] Univ Rochester James P Wilmot Canc Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA
关键词
acute myeloid leukemia; Aurora A kinase inhibitor; Aurora B kinase inhibitor; Aurora kinase inhibitors; non-Hodgkin's lymphoma; multiple myeloma;
D O I
10.1177/2040620715607415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the last two decades, since the discovery of Drosophila mutants in 1995, much effort has been made to understand Aurora kinase biology. Three mammalian subtypes have been identified thus far which include the Aurora A, B and C kinases. These regulatory proteins specifically work at the cytoskeleton and chromosomal structures between the kinetochores and have vital functions in the early phases of the mitotic cell cycle. Today, there are multiple phase I and phase II clinical trials as well as numerous preclinical studies taking place looking at Aurora kinase inhibitors in both hematologic and solid malignancies. This review focuses on the preclinical and clinical development of Aurora kinase inhibitors in hematological malignancy and discusses their therapeutic potential.
引用
收藏
页码:282 / 294
页数:13
相关论文
共 50 条
  • [1] Recent advances in treatment for hematological malignancies
    Tamura, Kazuo
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Progress in the development of selective inhibitors of Aurora kinases
    Mortlock, A
    Keen, NJ
    Jung, FH
    Heron, NM
    Foote, KM
    Wilkinson, R
    Green, S
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) : 199 - 213
  • [3] Immunotherapy in hematological malignancies: recent advances and open questions
    Tawfik, Essam A.
    Aldrak, Norah A.
    Albrahim, Shahad H.
    Alzahrani, Dunia A.
    Alfassam, Haya A.
    Alkoblan, Samar M.
    Almalik, Abdulaziz M.
    Chen, Kok-Siong
    Abou-Khalil, Rana
    Shah, Khalid
    Zaidan, Nada M.
    IMMUNOTHERAPY, 2021, 13 (14) : 1215 - 1230
  • [4] Recent Advances in the Field of Kinases and Kinase Inhibitors
    Huang, Zunnan
    Lee, Mee-Hyun
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (29) : 4207 - 4208
  • [5] Syk inhibitors in clinical development for hematological malignancies
    Delong Liu
    Aleksandra Mamorska-Dyga
    Journal of Hematology & Oncology, 10
  • [6] Syk inhibitors in clinical development for hematological malignancies
    Liu, Delong
    Mamorska-Dyga, Aleksandra
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [7] Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
    Sun, Wenyue
    Hu, Shunfeng
    Wang, Xin
    CANCER COMMUNICATIONS, 2024, 44 (09) : 1071 - 1097
  • [8] Targeting macrophages in hematological malignancies: recent advances and future directions
    Li, Wei
    Wang, Fang
    Guo, Rongqun
    Bian, Zhilei
    Song, Yongping
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [9] Targeting macrophages in hematological malignancies: recent advances and future directions
    Wei Li
    Fang Wang
    Rongqun Guo
    Zhilei Bian
    Yongping Song
    Journal of Hematology & Oncology, 15
  • [10] Characterization of small molecule inhibitors of the PIM kinases in in vitro models of hematological malignancies
    Sastri, Christine E.
    Guerrero, Nadia
    Yu, Dongyin
    Mattson, Bethany
    Dellamaggiore, Ken
    Yang, Yajing
    Hughes, Paul
    Wang, Hui-Ling
    Cee, Victor
    Lanman, Brian A.
    Pettus, Liping
    Reed, Anthony B.
    Wu, Bin
    Wurz, Ryan
    Tasker, Andrew
    Huang, Li-Ya
    Branstetter, Daniel
    Rex, Karen
    Winston, Jeffrey
    Burgess, Teresa L.
    Kendall, Richard
    Lipford, J. Russell
    CANCER RESEARCH, 2015, 75